SCHEMBL18277670

SCHEMBL18277670

CCCCc1cc(C(=O)O)n(-c2cccc(C)c2)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RPA1 P27694 1/20 0.46
▸ CNR1 P21554 1/20 0.45
▸ CNR2 P34972 1/20 0.45
▸ KLKB1 P03952 2/20 0.43
▸ ALDH1A1 P00352 3/20 0.43
▸ GAA P10253 1/20 0.43
▸ GRN P28799 1/20 0.42
▸ SORT1 Q99523 1/20 0.42
▸ F2 P00734 2/20 0.42
▸ F10 P00742 2/20 0.42
▸ PRSS1 P07477 2/20 0.42
▸ PRSS2 P07478 2/20 0.42
▸ PRSS3 P35030 2/20 0.42
▸ MEN1 O00255 2/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ ALOX5 P09917 1/20 0.41
▸ HSD11B1 P28845 1/20 0.41
▸ LMNA P02545 2/20 0.40
▸ NOTUM Q6P988 1/20 0.39
▸ CTSK P43235 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27889993 0.86 HTT (0.51) CNR1CNR2KLKB1ALDH1A1GAA
SCHEMBL3831066 0.83 NOTUM (0.43) CNR1CNR2KLKB1ALDH1A1GAA
SCHEMBL23401576 0.83 CNR1 (0.47) RPA1CNR1CNR2ALDH1A1KMT2A
SCHEMBL27795107 0.80 ALDH1A1 (0.59) CNR1CNR2ALDH1A1GAAGRN
SCHEMBL6420468 0.78 ALDH1A1 (0.58) RPA1ALDH1A1GAAGRNSORT1
SCHEMBL20015949 0.78 ALOX5 (0.44) CNR1CNR2ALDH1A1GAAGRN
SCHEMBL17369126 0.76 ALDH1A1 (0.59) RPA1CNR1CNR2KLKB1ALDH1A1
SCHEMBL30979685 0.75 KMT2A (0.54) RPA1ALDH1A1GAAMEN1KMT2A
SCHEMBL17361343 0.75 ALDH1A1 (0.44) RPA1KLKB1ALDH1A1GAAGRN
SCHEMBL20015969 0.75 SCN9A (0.42) CNR1CNR2ALDH1A1F2F10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160355510-A1 1 -(5-TERT-BUTYL-2-ARYL-PYRAZOL-3-YL)-3-[2-FLUORO-4-[(3-OXO-4H-PYRIDO[2, 3-B]PYRAZIN-8-YL)OXY]PHENYL]UREA DERIVATIVES AS RAF INHIBITORS FOR THE TREATMENT OF CANCER CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2016-12-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160355510-A1 1 -(5-TERT-BUTYL-2-ARYL-PYRAZOL-3-YL)-3-[2-FLUORO-4-[(3-OXO-4H-PYRIDO[2, 3-B]PYRAZIN-8-YL)OXY]PHENYL]UREA DERIVATIVES AS RAF INHIBITORS FOR THE TREATMENT OF CANCER BRAF, NRAS, LCK RPA1 1886/4885CNR1 3308/4885CNR2 2183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback